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AbstrACt
Objectives In many current guidelines, blood pressure 
(BP)-lowering drug treatment for primary prevention of 
cardiovascular disease (CVD) is based on absolute risk. 
However, in clinical practice, therapeutic decisions are often 
based on BP levels alone. We sought to investigate which 
approach was superior by conducting a post hoc analysis 
of the Australian National Blood Pressure (ANBP) cohort, a 
seminal study establishing the efficacy of BP lowering in ‘mild 
hypertensive’ persons.
Design A post hoc subgroup analysis of the ANBP trial 
results by baseline absolute risk tertile.
setting and participants 3244 participants aged 35–69 
years in a community-based randomised placebo controlled 
trial of blood pressure-lowering medication.
Interventions Chlorothiazide500 mg versus placebo.
Primary outcome measures All-cause mortality and non-
fatal events (non-fatal CVD, congestive cardiac failure, renal 
failure, hypertensive retinopathy or encephalopathy).
results Treatment effects were assessed by HR, absolute 
risk reduction and number needed to treat. Participants 
had an average 5-year CVD risk in the intermediate 
range (10.5±6.5) with moderately elevated BP (mean 
159/103 mmHg) and were middle aged (52±8 years). In a 
subgroup analysis, the relative effects (HR) and absolute 
effects (absolute risk reduction and number needed to 
treat) did not statistically differ across the three risk groups 
except for the absolute benefit in all-cause mortality (p for 
heterogeneity=0.04). With respect to absolute benefit, drug 
treatment significantly reduced the number of events in the 
high-risk group regarding any event with a number needed 
to treat of 18 (10 to 64), death from any cause with 45 (25 to 
196) and major CVD events with 23 (12 to 193).
Conclusion Our analysis confirms that the benefit of 
treatment was substantial only in the high-risk tertile, 
reaffirming the rationale of treating elevated blood pressure in 
the setting of all risk factors rather than in isolation.
IntrODuCtIOn
For decades, cardiovascular disease (CVD) 
has remained the greatest burden of disease 
in the developed world and now also in the 
developing world.1 2 In 2012, CVD was respon-
sible for 17.5 million deaths in the world 
and more than 20 000 deaths in Australia.1 3 
Noticeably, nearly 50% of deaths from CVD 
are attributable to high blood pressure (BP), 
the most common modifiable population risk 
factor.4 Drug therapy for primary prevention 
of CVD is now recommended to be based 
on absolute CVD risk, where BP-lowering 
drug treatment is determined by BP level 
together with other major CVD risk factors 
(eg, sex, age, total cholesterol, high-density 
lipoprotein cholesterol (HDLc), diabetes and 
smoking status) as an integrated score.5–9 Yet 
clinicians are reticent to treat systolic BP in 
those below 140 mmHg at high risk as well as 
not treating patients at low risk with BP above 
this threshold. There is a paucity of litera-
ture on the effects of lowering BP in low to 
moderate CVD risk individuals with grade 1 
hypertension (systolic BP from 140 mmHg 
to 159 mmHg and/or diastolic BP from 
90 mmHg to 99 mmHg) and some debate 
regarding its benefit.10 Guidelines from the 
US and Europe focus on BP thresholds and 
strengths and limitations of this study
 ► Our analysis provides further justification that an 
absolute risk strategy is superior to management 
based on the BP level alone in identifying those who 
are most likely to benefit from therapy.
 ► The statistical power to detect treatment effects was 
limited in this study, and this is a post hoc subgroup 
analysis.
 ► Due to the lack of high-density lipoprotein choles-
terol (HDLc) in the original data set, the HDLc used 
in the analyses was imputed from a 1980s national 
survey. The use of these imputed values is unlikely 
to greatly affect the risk stratification.
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promote early drug treatment due to the potential bene-
fits of earlier intervention and potential adverse effects 
of delayed intervention.6–8 11–13 JNC 811 recommends 
initiating drug treatment at the threshold of 150 mmHg 
systolic BP or 90 mmHg diastolic BP for the general popu-
lation at 60 years or older. This revised recommendation 
has caused controversy among clinicians who argue that 
drug treatments need to be initiated at a lower systolic 
BP of 140 mmHg, as previously recommended in JNC 
714; otherwise, patients are exposed to increased risk.15–18 
Similarly, the 2016 European Society of Cardiology guide-
lines recommend considering BP-lowering drug treat-
ment when systolic BP is greater than 140 mmHg and/or 
diastolic BP is greater than 90 mmHg after a reasonable 
period of time with lifestyle choice.7 Recently, the Systolic 
Blood Pressure Intervention (SPRINT) trial19 reported 
a significant benefit from intensive treatment to a target 
BP of 120 mmHg rather than 140 mmHg. However, this 
benefit was observed in those at high CVD risk without 
diabetes. In agreement with the findings from the 
SPRINT trial, guidelines in Australia,5 New Zealand,20 
UK8 and Canada9 recommend BP-lowering medication 
based on absolute CVD risk, recommending BP-lowering 
treatment as soon as possible in high CVD risk individ-
uals, but not in the low-risk to moderate-risk population 
unless BP persistently exceeds 160/100 mmHg.
Other groups21 have recommended early drug treat-
ment of grade 1 hypertension even in patients at low 
risk with the exception of patients with grade 1 ‘isolated’ 
hypertension, based on a meta-analysis by Thomopoulos 
et al22 and the HOPE-3 study.23 In contrast, a Cochrane 
review by Diao et al10 concluded that there was no statis-
tically significant effect of BP treatment in individuals 
who had grade 1 hypertension. The 2015 Blood Pressure 
Lowering Treatment Trialists Collaboration24 (BPLTTC) 
meta-analysis reported a statistically significant benefit 
of BP-lowering drug treatment in grade 1 hypertension 
in terms of stroke and all-cause mortality. However, the 
effects seen in the BPLTTC analysis could reflect differ-
ences in the BPLTTC sample that included participants 
who had diabetes, had a higher baseline risk and had 
previously received drug treatment. In another analysis 
of the BPLTTC individual patient data25 by absolute 
CVD risk at baseline showed a continuously increasing 
benefit with baseline risk.25 The BPLTTC study, however, 
included participants who both did and did not have a 
history of CVD.
Thus, we sought to reanalyse a seminal study used 
to justify treating individuals with elevated BP to see if 
stratification by baseline CVD risk would be a superior 
method for identifying candidates for BP-lowering medi-
cation in a treatment-naïve population. In this study, we 
compared the effectiveness of BP-lowering drug treat-
ment by a post hoc subgroup analysis of the Australian 
National Blood Pressure (ANBP) study.26 We restricted 
the analysis group to individuals with no history of CVD 
or diabetes and who were naïve to BP-lowering treatment. 
We selected this historical study because it was placebo 
controlled and patients in the control arm of the study 
would not have been taking a BP-lowering medication 
previously unless they had very high levels of BP. Our aim 
was to assess which group of individuals classified by abso-
lute risk benefited from active treatment versus placebo 
for CVD events within this seminal study that underwrote 
the treatment of elevated BP by BP thresholds.
MethODs
We performed a post hoc analysis of the ANBP study26. 
The study was conducted between 1973 and 1979 and was 
a multicentre, single-blind randomised controlled trial of 
3427 patients that compared the effects of BP-lowering 
drug therapy between individuals who initially received 
active treatment (chlorothiazide) and those who received 
delayed active treatment or no active treatment (placebo). 
The study intervention remains applicable to current prac-
tice as thiazide diuretics (eg, hydrochlorothiazide) are still 
first-line BP-lowering agents.5–9 The ANBP study enrolled 
participants who had not been on treatment for hyperten-
sion in the past 3 months and had no history of CVD or 
diabetes. In the 1970s, ‘mild hypertension’ was defined as 
a screening diastolic BP of 95–109 mmHg with a systolic 
BP lower than 200 mmHg. A total of 3931 eligible partic-
ipants were initially randomised, then 504 participants 
were excluded because their BP throughout the study did 
not meet the criteria for starting drug treatment (entry 
or follow-up diastolic BP higher than 95 mmHg and/or 
entry or follow-up systolic BP higher than 200 mmHg). The 
primary endpoints were all-cause mortality and non-fatal 
events (non-fatal CVD, congestive cardiac failure, renal 
failure, hypertensive retinopathy or encephalopathy).26
risk stratification
In this analysis, the baseline absolute CVD risk was calcu-
lated according to the 5-year Framingham absolute risk 
score.27 The Framingham score was chosen because it is 
currently recommended in the National Vascular Disease 
Prevention Alliance (NVDPA) guidelines5 in Australia. 
The sample was restricted to 3244 participants who were 
older than 35 years and was stratified by tertile of estimated 
5-year CVD risk score. We also classified participants with 
very high BP (systolic BP ≥180 mmHg and/or diastolic 
BP ≥110 mmHg) or total cholesterol (>7.5 mmol/L) values 
the highest risk tertile regardless of their risk score, as per 
the Australian guidelines.5 The ANBP dataset included all 
variables required for CVD risk calculation except HDLc. 
The HDLc value was imputed from the Australian National 
Heart Foundation risk factor prevalence study as this was 
near contemporaneous with the ANBP.28 Mean value of 
HDLc was categorised by age and sex. In a sensitivity anal-
ysis, we stratified the sample by Globorisk score,29 a CVD 
risk score that does not require HDLc value and is validated 
in individuals over 40 years. The equation for the Austra-
lian population was obtained by personal contact with the 
author (Peter Ueda, unpublished data, 2016). This anal-
ysis excluded 471 participants younger than 40 years. Less 
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than 1% of the study participants had data missing for 
total cholesterol, weight and/or height, and these missing 
data were managed by multiple imputation using chained 
equations.
statistical analysis
All analyses were based on the modified ‘intention to treat’ 
principle. We included participants who had withdrawn 
from the study by their group allocation at randomisation 
in all analyses. The differences in baseline characteristics 
between ‘active group’ and ‘placebo group’ were tested by 
analysis of variance test for continuous variables and χ2 test 
for categorical variables. Treatment effects were assessed by 
HR, absolute risk reduction (ARR) and number needed to 
treat (NNT). The HRs and corresponding 95% CIs were esti-
mated by Cox proportional hazard model after adjusting for 
clustering of participants within community-based centres 
and potential risk factors including baseline characteris-
tics. The proportional assumption was checked by the test 
for interaction of HR with time. ARR and NNT were esti-
mated from Kaplan-Meier curves at the median of follow-up 
time (4.4 years).30 Tests for interaction of treatment effect 
over the subgroups were obtained by the Cox regression 
model for the HR and a Cochran’s Q test for the ARR. The 
threshold for significance for treatment effect was set at 
0.05 for the main analysis and subgroup analysis. Only one 
subgroup analysis with related outcomes was conducted; 
thus, multiplicity was not likely to affect our results.
results
Patient characteristics
Table 1 provides baseline characteristics of the partic-
ipants stratified by the tertile of CVD risk score. On 
average, study participants had intermediate 5-year CVD 
risk as referred in the NVDPA guideline (10.5±6.5) with 
moderately elevated BP (mean 159/103 mmHg) and 
were middle aged (52±8). The tertiles had estimated 
5-year CVD risks of less than 6.1% (low), 6.1%–17.0% 
(moderate) and more than 17.0% (high). These values 
are similar to the thresholds recommended by the 
Australian NVDPA guideline5 for low (<10%), moderate 
(10%–15%) and high risk categorisation (>15%). The 
distribution of baseline characteristics by treatment 
assignment was not significantly different except for body 
mass index (BMI) in the total population, the number of 
smokers in the low-risk group, systolic BP and BMI in the 
moderate-risk group.
Approximately one-third of the participants (34.5%) 
prematurely stopped study treatment due to decisions by 
clinics, participants’ doctors and the participant them-
selves, or for unknown reasons (table 2). Participants’ 
doctors were more likely to stop placebo treatment in 
all three risk groups, whereas clinics withdrew more 
BP-lowering drug-randomised participants in the low-risk 
group and the high-risk group. No substantial difference 
in baseline characteristics between the two randomised 
treatment groups was recorded in any risk group.
effect of bP-lowering drug treatment on total study population
During a median follow-up of 4.4 years (IQR 1.0–5.9), 
257 major CVD events (7.9%) were observed, in which 
ischaemic heart disease accounted for 203 events (6.3%), 
stroke accounted for 48 events (1.5%) and congestive 
heart failure accounted for six events (0.2%).
After adjustment for sex, age, BMI, smoking, systolic BP 
at baseline and study centres, BP-lowering treatment was 
associated with a 15% reduction in non-fatal events and a 
25% reduction in all-cause mortality (figure 1), although 
the treatment effects were not statistically significant. 
Similar effects were found in the secondary endpoints 
including any events HR 0.82 (0.65–1.03), major CVD 
events HR 0.83 (0.65–1.07) and non-fatal CVD events HR 
0.87 (0.67–1.13). We identified a marginally significant 
effect in stroke HR 0.55 (0.3–1.001).
effect of bP-lowering drug treatment on 5-year CVD risk 
groups
In the subgroup analysis, the magnitude of relative treat-
ment effect increased from low to high CVD risk group, 
Table 1 Baseline characteristics stratified by tertile of baseline CVD risk score
Group variable Total
Low
(<6.1%)
Moderate
(6.1%–17.0%)
High
(>17.0%)
Sample, N 3244 1082 1081 1081
Randomised to active treatment, N (%) 1622 (50%) 559 (51.7%) 513 (47.5) 550 (50.9)
Age, years 51.7±8.1 46.0±6.2 54.5±6.5 54.6±8.1
Male sex, N (%) 2017 (62.2) 567 (52.4) 804 (74.4) 646 (59.8)
Current smoker, N (%) 801 (24.7) 115 (10.6) 352 (32.6) 334 (30.9)
SBP, mmHg 159.5±17.5 148.4±12.2 157.3±12.2 172.6±17.9
DBP, mmHg 102.9±6.8 100.0±3.8 100.8±4.4 107.9±8.2
Total cholesterol, mmol/L 6.0±1.1 5.5±0.9 6.0±0.9 6.5±1.3
BMI, kg/m2 26.6±3.9 26.6±4.0 26.5±3.6 26.7±4.1
Bold values: P<0.05 based on the distribution of baseline characteristics by treatment assignment.
BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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though the benefits were not statistically significant in the 
high-risk group in terms of all-cause mortality 0.60 (0.26–
1.40) and major CVD event with HR 0.76 (0.52–1.10).
The increasing trend for the benefit was also observed 
when comparing the absolute treatment effects ARR 
among the three risk groups. No evidence of heteroge-
neity was observed except the effect in the major CVD 
event. Substantial effects of BP-lowering treatment 
were produced in the high-risk group regarding any 
trial endpoints (ARR 5.6 (95% CI 1.6 to 9.6)), all-cause 
mortality (ARR 2.2 (95% CI 0.5 to 3.9)) and any CVD event 
(4.3 (95% CI 0.5 to 8.1)) (table 3). Treating 18 high-risk 
participants for 4 years prevented one trial event, treating 
45 prevented one death and treating 23 prevented one 
CVD event. In contrast, treating low or moderate-risk 
participants needed much higher numbers to prevent 
one event or possibly caused net harm (table 3). Also, 
a sensitivity analysis by using the GLOBORISK score,29 
which does not require HDLc, was consistent with our 
original findings, except that the ARR in major CVD 
event is no longer statistically significant with ARR 3.4% 
(−0.4% to 7.3%, P=0.08).
DIsCussIOn
In our post hoc analysis of the ANBP study, we found 
evidence of benefit from BP-lowering treatment in the 
high-risk tertile for primary trial endpoints of any event 
and any CVD event with low or moderate-risk partici-
pants unlikely to benefit. Our study population had an 
overall moderate 5-year CVD risk (10.5%) and moder-
ately elevated systolic BP (mean 159/103 mmHg) by 
modern definitions. The ANBP study aimed to treat ‘mild 
hypertension’ (according to the old definition) that 
Table 2 Characteristics of those who prematurely stopped study regimen
Group variable Total
Low
(<6.1%)
Moderate
(6.1%–17.0%)
High 
(>17.0%)
Sample, N 1119 404 346 369
Randomised to active treatment, N (%) 531 (47.5) 204 (50.5) 151 (43.6) 176 (47.7)
Age, years 51.2±8.3 45.9±6.4 54.1±7.0 54.2±8.5
Male sex, N (%) 626 (55.9) 188 (46.5) 243 (70.2) 195 (52.9)
Current smoker, N (%) 321 (28.7) 58 (14.4) 143 (41.3) 120 (32.5)
SBP, mmHg 159.1±18.1 147.6±12.9 157.0±11.9 173.7±17.7
DBP, mmHg 102.9±6.8 100.0±4.0 100.6±4.2 108.1±8.2
Total cholesterol, mmol/L 6.0±1.1 5.5±0.9 6.0±0.9 6.4±1.3
BMI, kg/m2 26.7±4.1 26.7±4.0 26.6±3.9 26.8±4.5
Reason for stopping
  Clinic, N (%) 204 (18.2) 74 (18.3) 75 (21.7) 55 (14.9)
  Local doctor, N (%) 287 (25.7) 98 (24.3) 87 (25.1) 102 (27.6)
  Participants, N (%) 548 (49.0) 204 (50.5) 162 (46.8) 182 (49.3)
  Not known, N (%) 80 (7.2) 28 (6.9) 22 (6.4) 30 (8.1)
Bold values: P<0.05 based on the distribution of baseline characteristics by treatment assignment.
BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
Figure 1 Effect of treatment in the overall study population. *Adjusted for age, sex, body mass index, screening centres, 
smoking and systolic blood pressure. Bold values: P<0.05. CHD, coronary heart disease; CVD, cardiovascular disease.
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was primarily defined by diastolic BP. Some randomised 
participants were excluded from the original analysis 
because they did not meet the criteria for starting BP-low-
ering drug treatment postrandomisation. This would not 
be seen in modern clinical trials. In our reanalysis, we 
found that BP-lowering drug treatment reduced the risk 
of major CVD events and all-cause mortality, but the effect 
was not statistically significant. This is likely to be due to 
reduced power as the cohort was analysed by tertile of 
absolute risk, as well as by the two groups of randomised 
therapy. The original study found a statistically significant 
reduction in the incidence of CVD mortality and all trial 
endpoints, using the full dataset and a risk ratio (RR) 
rather than time-to-event analysis.26
In our analysis of subgroups defined by CVD risk score, 
the magnitude of relative treatment effects (relative risk 
reduction) on all-cause mortality and major CVD events 
increased across all three CVD risk group from low to 
high risk, without statistically significant heterogeneity 
(P=0.78 for all-cause mortality and P=0.62 for the major 
CVD event) (table 3). All relative treatment effects in our 
analysis measured by HRs were adjusted by age, sex, BMI, 
smoking, screening centres and systolic BP. However, no 
significant difference was observed between adjusted and 
unadjusted HRs. In terms of absolute benefits, risk reduc-
tion linearly increased across the CVD risk group from 
low to high risk. BP-lowering drug treatment produced 
an unclear benefit in the low and intermediate CVD 
risk group but a significant benefit in the high CVD risk 
group. Heterogeneity of absolute effects across the CVD 
risk groups was only significant in all-cause mortality 
(P=0.04).
Regarding the benefit of BP-lowering drug treatment in 
the low to intermediate CVD risk population, our results 
Table 3 Effect of treatment by tertile of baseline CVD risk score
Active placebo Adjusted HR
(95% CI)*
ARR %
(95% CI)† NNTEvent (rate per 1000 patient-year)
Any event
  Low 22 (8.9) 23 (10.0) 0.94 (0.52 to 1.70) −0.3 (−2.7 to 2,1) −370 (−37 to 47)
  Moderate 56 (26.1) 67 (28.0) 0.93 (0.65 to 1.33) 1.1 (−2.9 to 5.2) 87 (−34 to 19)
  High 59 (24.8) 75 (33.2) 0.75 (0.53 to 1.06) 5.6 (1.6 to 9.6) 18 (10 to 64)
  P value − − 0.64 0.05 −
All-cause mortality
  Low 6 (2.4) 6 (2.5) 0.96 (0.30 to 3.01) −0.5 (−1.6 to 0.7) −213 (−63 to 153)
  Moderate 10 (4.4) 13 (5.1) 0.81 (0.35 to 1.86) 0.2 (−1.7 to 2.1) 476 (−60 to 48)
  High 9 (3.5) 14 (5.7) 0.60 (0.26 to 1.40) 2.2 (0.5 to 3.9) 45 (25 to 196)
  P value − − 0.78 0.04 −
Non-fatal event
  Low 16 (6.4) 17 (7.4) 0.93 (0.47 to 1.87) 0.2 (−1.9 to 2.3) 476 (−52 to 43)
  Moderate 46 (21.3) 54 (22.2) 0.96 (0.65 to 1.43) 0.9 (−2.8 to 4.5) 118 (−35 to 22)
  High 50 (20.9) 61 (26.6) 0.80 (0.55 to 1.16) 3.3 (−0.4 to 7.0) 30 (−249 to 14)
  P value − − 0.77 0.36 −
Major CVD event
  Low 17 (6.8) 18 (7.8) 0.98 (0.50 to 1.91) 0.2 (−1.9 to 2.3) 476 (−52 to 43)
  Moderate 50 (23.2) 58 (24.0 0.98 (0.67 to 1.43) 0.6 (−3.2 to 4.5) 164 (−31 to 22)
  High 50 (20.9) 64 (28.0) 0.76 (0.52 to 1.10) 4.3 (0.5 to 8.1) 23 (12 to 193)
  P value − − 0.62 0.17 −
Any CHD
  Low 17 (6.8) 14 (6.0) 1.21 (0.59 to 2.48) −0.4 (−2.4 to 1.6) −256 (−41 to 61)
  Moderate 39 (17.9) 47 (19.2) 0.93 (0.60 to 1.42) 1.1 (−3.0 to 5.1) 94 (−33 to 19)
  High 41 (17.0) 45 (19.2) 0.90 (0.59 to 1.37) 1.9 (−1.4 to 5.3) 52 (−72 to 19)
  P value − − 0.83 0.47 −
Bold values: P<0.05.
P value indicated p for interaction.
*Adjusted for age, sex, body mass index, smoking, screening centres and systolic blood pressure.
†As estimated by the Kaplan-Meier curve.
ARR, absolute risk reduction; CHD, coronary heart disease; CVD, cardiovascular disease; NNT, number needed to treat; NNTB, NNT (benefit); 
NNTH, NNT (harm).
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from main and subgroup analyses match well with the 
study outcomes from the HOPE-3 trial23 and the Diao 
review.10 In the HOPE-3 trial,23 no benefit of intensive 
drug treatment was established in the intermediate-risk 
persons with HR 0.98 (0.84–1.14) for all-cause mortality 
and HR 0.92 (0.79–1.06) for major CVD events referred 
as a first secondary outcome in the paper. At baseline, 
the HOPE-3 participants were older (65 years) and had 
a lower level of BP (138.1/81.9 mmHg) compared with 
the ANBP participants. One reason for the lower BPs 
may be due to the 4-week run-in phase in which all of 
the HOPE-3 participants received active BP-lowering 
drug treatment before randomisation, and one-fifth of all 
eligible participants had previously received drug treat-
ment before the trial. In 2012, Diao et al reviewed placebo 
randomised controlled trials in grade 1 hypertension and 
also found no beneficial effect of drug treatment with a 
RR 0.85 (0.63–1.15) for all-cause mortality and RR 0.97 
(0.2–1.32) for major CVD events.10 The participants in 
the Diao review were likely to have a lower CVD risk than 
those in the ANBP and the HOPE-3 trials, with major 
CVD events occurring in only 2.4% of participants in the 
placebo group. Following a similar approach, in 2015, 
the BPLTTC24 reviewed randomised controlled trials in 
grade 1 hypertension but extended to trials comparing 
active or more intensive regimens and placebo or less 
intensive regimens. In line with the findings from the 
2015 BPLTTC study, we identified a marginally signif-
icant effect on stroke, yet our effect estimates with an 
HR 0.75 (0.45–1.36) for total deaths and an HR 0.83 
(0.65–1.07) for major CVD events slightly differed from 
the 2015 BPLTTC study’s results with an OR 0.78 (0.67–
0.92) and an OR 0.86 (0.74–1.01) correspondingly. The 
differences in CIs may be due to the difference in sample 
sizes and baseline characteristics. It is more likely that 
the 2015 BPLTTC participants had higher CVD risk and 
higher BP value at baseline when about 40% of 15 266 
participants had diabetes and about 23% had previously 
received BP-lowering drug treatment. Our study and the 
2015 review confirm the absolute benefits of BP-lowering 
drug treatment in high CVD risk population in terms of 
total deaths with ARR 2.2% (0.5% to 3.9%, P=0.01) for 
the ANBP and ARR 1.4% (0.5% to 2.2%) for the review. 
Furthermore, the benefit was also recorded in major 
CVD event with ARR 4.3% (0.5% to 8.1%, P=0.03) in the 
ANBP, whereas the 2015 BPLTTC observed a non-signif-
icant effect with ARR 1.0% (−0.1% to 1.9%). The differ-
ence can be explained in part by the study design when 
more than 50% of participants with systolic BP higher 
than 160 mmHg in eligible studies in the 2015 BPLTTC 
were excluded. The distribution of these excluded partic-
ipants might not be even between active arm and control 
arm, thus biasing the treatment effects.
In another subgroup analysis stratified by tertile of 
baseline systolic BP (online supplement), the mean value 
of CVD risk varied from low to high corresponding to 
the lowest and the highest tertile. The relative treatment 
benefits were not statistically significant, but in terms of 
absolute effects, BP-lowering drug treatment substantially 
reduced any trial events, all-cause mortality and major 
CVD events within the highest tertile. The findings were 
in line with what we found in the CVD risk-stratified 
subgroup when all participants in the highest BP-strati-
fied tertile had high CVD risk score (20.7±9.5). However, 
the heterogeneity of treatment effects among the three 
subgroups in analysis by baseline systolic BP was no longer 
significant as it was in the subgroup analysis by CVD risk 
score. Furthermore, the trend of lower to higher absolute 
benefit from low-risk to high-risk groups that was seen for 
CVD risk was not apparent when groups are defined by BP 
alone. Thus, in this study, CVD risk score identified those 
who most benefited from BP-lowering drug treatment.
limitations
There are a number of limitations of our study. First, 
statistical power is unavoidably decreased in a post hoc 
subgroup analysis, and the multivariate Framingham risk 
score used in our analysis has not been well validated 
within the Australian population.31 However, using a 
multivariate score for stratification is known to increase 
the power to detect heterogeneity in absolute risk benefit 
over subgroup analyses that are based on individual 
risk factors.32 A prospective study to address the issue 
of whether there is an advantage in treating BP by abso-
lute risk is unlikely to be performed, because of the very 
large sample size and very long follow-up time required, 
particularly in patients at low risk. Therefore, reanalysis 
of the early placebo-controlled trials seems to be the most 
feasible approach for assessing the effects of delayed 
versus early drug treatment in individuals with varying 
CVD risk together and elevated BP.
Second, the estimation of HDLc from the 1980s national 
survey may alter the CVD risk score, but we do not believe 
this method greatly affected the risk stratification because 
a 0.4 difference in the HDL estimate only results in a 0.01 
difference in CVD risk score. Furthermore, no associa-
tion between HDLc and BP has been observed.33 34 The 
sensitivity analysis using Globorisk score29 without HDLc 
showed similar results as our main analysis. Although the 
ARR is no longer statistically significant, this result is likely 
due to the smaller sample size and subsequent number of 
events. In conclusion, the sensitivity analysis supports our 
main analysis.
Third, the paucity of trial endpoints in each CVD 
risk group prevented us from comparing the effects 
in some specific outcomes with respect to stroke and 
deaths from CVD. In addition, approximately one-third 
of the participants prematurely stopped randomised 
drug treatment. However, this pattern likely reflects the 
typical situation to occur in actual clinical practice, and 
this analysis is conducted on an intention-to-treat basis, 
so any difference in the estimate of treatment effect due 
to non-adherence is deliberately retained. Most partici-
pants were followed throughout the trial, except those 
with an unknown reason for stopping: loss to follow-up 
(7.2%). An analysis with further adjustment by variable 
7Ho CLB, et al. BMJ Open 2018;8:e017723. doi:10.1136/bmjopen-2017-017723
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‘premature stopped study treatment’ did not substantially 
change our findings, except effects on stroke in general 
population became statistically significant (0.55, 95% CI 
0.30 to 0.99, P=0.05). This is because non-adherence is 
balanced between the allocated treatment groups.
In conclusion, our research has demonstrated that drug 
treatment in patients with elevated BP is best directed to 
those at high risk of incident CVD events. This reinforces 
the guidelines recommendation to treat based on abso-
lute (or global) CVD risk, rather than according to BP 
thresholds alone.5–9
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